Céline Chapelle: Evaluating 6-Month Risks of Recurrent VTE and Major Bleeding With Tinzaparin
Céline Chapelle, Biostatistician at Saint-Étienne University Hospital, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“New Research Alert!
I am excited to share our latest co-authored study, now published in Blood Advances, focusing on the management of Cancer-Associated Thrombosis (CAT).
Using pooled data from 1,413 patients, we evaluated the 6-month risks of recurrent VTE and major bleeding (MB) in patients treated with tinzaparin.
Our findings reveal a critical nuance in how we view patient risk:
- Tumor Site Matters: Recurrent VTE risk surpassed bleeding risk in lung and GI cancers, while the opposite was true for breast cancer.
- The ‘Frailty’ Factor: In frail patients (age greater than or equal to 75, low body weight, or renal impairment), the risk of VTE recurrence increases with the number of frailty factors—yet, surprisingly, the risk of major bleeding remains relatively stable.
- Clinical Takeaway: In frail patients with CAT, the risk of VTE recurrence outweighs the risk of bleeding. Our findings suggest that standard full-dose tinzaparin should be maintained in this population.
This study underscores that in CAT, one size does not fit all. Understanding the specific interplay between tumor site and patient frailty is key to optimizing anticoagulation.
A huge thank you to my co-authors and the teams across the four prospective studies for this massive collaborative effort!”
Title: Complications in Cancer Associated Thrombosis patients on tinzaparin by cancer site and frailty: a pooled analysis
Authors: Isabelle Mahe, Celine Chapelle, Philippe Girard, Luis Jara-Palomares, Agnes YY Lee, Olivier Sanchez, Guy Meyer, Patrick Mismetti, Silvy Laporte
Read the Full Article on Blood Advances
Stay updated with Hemostasis Today.
-
May 31, 2026, 07:02Raising Awareness of Cerebral Venous Sinus Thrombosis in Women – NBCA
-
May 31, 2026, 07:00Ceri Roberts: How to Reduce Your Risk of a Blood Clot
-
May 31, 2026, 05:28Nikolaos Androulakis: Inflammatory Burden and Antiphospholipid Antibodies in Lupus Anticoagulant Testing
-
May 31, 2026, 05:28Alysha Arif: Understanding a Complex Case of Postpartum Seizures
-
May 31, 2026, 05:27Chiara Novelli: Are We Validating Laboratory Algorithms as Rigorously as We Validate Laboratory Tests?
-
May 31, 2026, 02:42Katja van den Hurk: Optimizing Iron Management in Blood Donors
-
May 31, 2026, 02:36The New JPAC Website Has Been Live for Nearly a Week – SHOT
-
May 31, 2026, 02:33Jecko Thachil: Is It Possible to Use Machine Learning for Differentiating Inherited Thrombocytopenia from Other Causes?
-
May 30, 2026, 18:12Khokon Miah Akanda: FDA Approves a First-in-Class Hypertension Drug